Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy (Q38674277)

5 September 2017

title

Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy (English)

1 reference

5 September 2017

main subject

angiogenesis inhibitor

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28718406%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Sergio Rey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28718406%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Luana Schito

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28718406%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Scott Eliasof

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28718406%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Robert S Kerbel

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28718406%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

publication date

10 June 2017

1 reference

5 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28718406%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28718406%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28718406%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

529-541

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28718406%20AND%20SRC:MED&resulttype=core&format=json

Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling

5 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Angiogenesis in cancer, vascular, rheumatoid and other disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Targeting hypoxia in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

The Tumor Microenvironment in Non–Small-Cell Lung Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Combined effects of pericytes in the tumor microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Molecular targeting of hypoxia in radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Hypoxia-Inducible Factors: Master Regulators of Cancer Progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Ten years of anti-vascular endothelial growth factor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

mTOR Signaling Confers Resistance to Targeted Cancer Drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Benefits of vascular normalization are dose and time dependent--letter.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Antiangiogenic therapy in oncology: current status and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Tumor cell vasculogenic mimicry: from controversy to therapeutic promise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Role of endothelial cell metabolism in vessel sprouting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Endothelial cell metabolism: parallels and divergences with cancer cell metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Understanding the Intersections between Metabolism and Cancer Biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Hypoxia and cellular metabolism in tumour pathophysiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

The role of fatty acid β-oxidation in lymphangiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Recent agents targeting HIF-1α for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

DNA topoisomerase poisons as antitumor drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Hypoxia regulates ABCG2 activity through the activivation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Targeting HIF2 in Clear Cell Renal Cell Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

The VHL/HIF axis in clear cell renal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Targeting renal cell carcinoma with a HIF-2 antagonist.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Molecular evolution of the metazoan PHD-HIF oxygen-sensing system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Regulation of angiogenesis by oxygen and metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Molecular mechanisms and clinical applications of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Metabolic reprogramming by HIF-1 promotes the survival of bone marrow–derived angiogenic cells in ischemic tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

The impact of hypoxia on tumor-associated macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRECAN.2017.05.002

10.1016/J.TRECAN.2017.05.002

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28718406%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28718406%20AND%20SRC:MED&resulttype=core&format=json